NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

病毒性結膜炎治療市場-市場規模/份額/展望/機會分析:2021-2028

Viral Conjunctivitis Drugs Market, by Drug Class, by Virus Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版商 Coherent Market Insights 商品編碼 1009429
出版日期 內容資訊 英文 214 Pages
商品交期: 2-3個工作天內
價格
病毒性結膜炎治療市場-市場規模/份額/展望/機會分析:2021-2028 Viral Conjunctivitis Drugs Market, by Drug Class, by Virus Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
出版日期: 2021年06月01日內容資訊: 英文 214 Pages
簡介

病毒性結膜炎是由腺病毒、單純皰疹病毒等多種病毒引起的急性結膜感染。病毒性結膜炎佔傳染性結膜炎的大部分,佔75%之多。市場公司正在進行臨床試驗,以開發有效的腺病毒結膜炎治療方法,這將有助於預測期內的市場增長。

本報告對全球病毒性結膜炎藥物市場進行研究和分析,並提供有關市場動態、細分市場分析、區域市場分析、競爭態勢等方面的系統信息。

目錄

第 1 章調查目標/先決條件

第 2 章市場概覽

第三章市場動態/監管/趨勢分析

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
  • 影響分析
  • 可疑急性結膜炎的臨床處理流程
  • 結膜炎關聯/易感性和典型的臨床症狀
  • PEST 分析
  • 其他眼病治療的建議
  • 行業趨勢
  • 管道分析
  • 主要亮點
  • 流行病學
  • 基於臨床症狀的病毒性結膜炎分類算法
  • NHI 價目表
  • 病毒性結膜炎藥物報銷方案
  • 監管場景
  • 全球供應鏈分析

第 4 章 COVID-19 的影響分析

  • COVID-19 的流行病學
  • COVID-19 對病毒性結膜炎治療供需的影響
  • COVID-19 對結膜炎藥物市場的影響

第 5 章全球病毒性結膜炎治療藥物市場:按藥物分類

  • 簡介
  • 人工淚液
  • 減充血劑
  • 抗組胺藥
  • 非甾體抗炎藥
  • 抗病毒藥物
  • 類固醇
  • 抗生素

第 6 章全球病毒性結膜炎治療市場:按病毒類型

  • 簡介
  • 腺病毒
  • 腸道病毒
  • 其他

第 7 章全球病毒性結膜炎治療藥物市場:按分銷渠道

  • 簡介
  • 醫院藥房
  • 零售藥店
  • 網上藥店

第 8 章全球病毒性結膜炎治療藥物市場:按地區

  • 簡介
  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章競爭形勢

  • 公司簡介
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Bausch Health Companies Inc.
    • Panoptes Pharma Ges.mbH
    • NovaBay Pharmaceuticals, Inc.
    • Nicox
    • NanoViricides Inc.
    • CuraMedical BV
    • Strategies.
    • Novartis International AG
    • Pfizer Inc.
    • Johnson &Johnson
    • GlaxoSmithKline Plc.
    • Okogen Inc.
  • 分析師見解

第10章 章節

目錄

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study:

  • This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market

Detailed Segmentation:

  • Global Viral Conjunctivitis Drugs Market, By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • Global Viral Conjunctivitis Drugs Market, By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • Global Viral Conjunctivitis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Viral Conjunctivitis Drugs Market, By Region:
    • North America
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Latin America
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Middle East
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • AbbVie Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox
  • NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Okogen Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Virus Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Algorithm for Clinical Approach to Suspected Acute Conjunctivitis
  • Associated/Predisposing Factors for and Typical Clinical Signs Of Conjunctivitis
  • PEST Analysis
  • Recommendations for Other Eye Disorder Treatment
  • Industry Trends
  • Pipeline Analysis
  • Key Highlights
  • Epidemiology
  • Algorithm for Classification of Viral Conjunctivitis based on Clinical Presentation
  • Drugs Pricing List
  • Reimbursement Scenario of Viral Conjunctivitis Drugs
  • Regulatory Scenario
  • Global Supply Chain Analysis

4. COVID - 19 Impact Analysis

  • COVID-19 Epidemiology
  • Impact of COVID-19 on Demand and Supply of Viral Conjunctivitis Drugs
  • Impact of Covid-19 on the Conjunctivitis Drugs Market

5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2017-2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Artificial tears
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Decongestants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-histamines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • NSAIDS
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-viral drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Steroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Antibiotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Adenovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Enterovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Viral Conjunctivitis Drugs Market, By Region, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Nicox
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • CuraMedical B.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies.
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact